Overview

Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine

Status:
Completed
Trial end date:
2020-12-28
Target enrollment:
Participant gender:
Summary
This pilot study aims to identify predictors of response to intranasal ketamine treatment in patients with treatment-resistant depression. Participants will give a sample of blood and undergo magnetic resonance imaging before and after a single intranasal ketamine treatment. Participants will subsequently receive a second intranasal ketamine treatment.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Dan Iosifescu
Treatments:
Ketamine